# How Small Funds Maintain a Shared Biotech Catalyst Calendar Canonical URL: https://biopharmsignal.com/use-cases/small-biotech-fund-teams/shared-biotech-catalyst-calendar Role: [Small Biotech Fund Teams](https://biopharmsignal.com/use-cases/small-biotech-fund-teams.md) Category: Catalyst management Last updated: 2026-07-26 Keep clinical readouts, PDUFA dates, conference presentations, and company guidance visible without relying on a fragile spreadsheet. ## The Situation Several portfolio and watchlist companies are approaching binary events in the same quarter. Some dates are fixed, while others are only management guidance such as “mid-year” or “in the second half.” ### Best Fit Portfolio managers, analysts, associates, and operations leads at small healthcare and event-driven investment funds. ## The Challenge A calendar can look precise even when the underlying date is not. The team must distinguish confirmed dates from estimated windows, track revisions, and connect each event to position size and preparation work. ## How To Think About The Task A catalyst calendar becomes a research tool only when it records uncertainty. A table of dates can create the appearance of control while hiding the difference between a fixed FDA deadline, a company-guided quarter, an inferred conference presentation, and an event that has already moved once. For a small fund, the calendar should coordinate three things at the same time: when an event may happen, when preparation must begin, and how much portfolio exposure depends on the outcome. The event date is only one field in that operating system. ### Use timing confidence as a first-class field Preserve the exact source language and give the timing a confidence label. “PDUFA date of October 12” is fundamentally different from “topline data expected in the second half.” Turning both into calendar dates erases useful information. A broad window should remain broad until a newer primary source narrows it. ### Schedule research deadlines before event deadlines A calendar should show when the preview memo, model update, physician call, or risk review must be completed. If preparation begins only when the event is imminent, the team may be forced to make decisions under the same time pressure as the rest of the market. Internal checkpoints create the option to reduce uncertainty earlier. ### Review the portfolio as a calendar, not just each company Several apparently unrelated tickers can create one crowded risk period. The calendar should reveal events that cluster in the same week as well as programs that share a target, modality, or regulatory precedent. That view helps the portfolio manager distinguish a list of catalysts from a concentrated set of assumptions. ## Illustrative Example ### Illustrative quarter with mixed date quality Imagine three holdings: one has a confirmed PDUFA date, one guides to a Phase 3 readout “late in the quarter,” and one expects data at a conference but has not yet confirmed abstract acceptance. A weak calendar may place all three on precise dates. A stronger calendar preserves the first as fixed, shows the second as a window, and treats the third as conditional. The team can then set different review points. The FDA event may require label-scenario work several weeks ahead. The clinical readout may need weekly guidance monitoring. The conference event may stay provisional until the program appears in the official schedule. ### Questions To Answer Before Making A Decision - What is the primary source and exact timing language? - Is the date fixed, guided, inferred, or conditional? - What research must be finished before the event window begins? - Which other portfolio events share timing or underlying risk? ## A Repeatable Workflow 1. Record the source and confidence level for every catalyst date or window. 2. Separate fixed regulatory dates from company-guided clinical timing and conference-dependent events. 3. Attach the affected ticker, program, thesis question, owner, and portfolio exposure. 4. Create review checkpoints before the event instead of waiting for the final date. 5. Update the calendar when guidance changes and preserve the previous date for accountability. ## Signals To Keep Visible - PDUFA and advisory committee dates - Topline and interim clinical data windows - Medical conference abstract and presentation dates - FDA meetings and regulatory submissions - Management changes to timing guidance ## Common Mistakes - Presenting estimated windows as confirmed dates - Tracking dates without source links - Ignoring concentration across correlated binary events ## Deliverable A shared catalyst calendar that shows timing confidence, event owner, preparation deadline, portfolio exposure, and the latest source. ## Practical Outcome The fund can see upcoming workload and risk concentration early, prepare research before the market focuses on the event, and detect timing changes without rebuilding the calendar. ## Where BioPharmSignal Fits Use LiveFeed and company pages for source-linked monitoring, the PDUFA Calendar for upcoming FDA milestones, and watchlists or alerts to keep relevant tickers and keywords visible. The workflow still requires independent research and judgment. ## Frequently Asked Questions ### Who is this workflow for? It is designed for small biotech fund teams and adjacent biotech research users who need a repeatable, source-linked way to complete this task. ### What should this workflow produce? A shared catalyst calendar that shows timing confidence, event owner, preparation deadline, portfolio exposure, and the latest source. ### What is the practical benefit? The fund can see upcoming workload and risk concentration early, prepare research before the market focuses on the event, and detect timing changes without rebuilding the calendar. ## Related Workflows - [How a Small Biotech Fund Builds a Daily News Briefing](https://biopharmsignal.com/use-cases/small-biotech-fund-teams/daily-biotech-news-briefing.md) - [How Small Funds Track Competitive Read-Throughs in Biotech](https://biopharmsignal.com/use-cases/small-biotech-fund-teams/competitive-read-throughs.md) - [How a Small Fund Prepares a Biotech Investment Committee Brief](https://biopharmsignal.com/use-cases/small-biotech-fund-teams/biotech-investment-committee-brief.md) Format note: This is an illustrative workflow guide, not a named customer testimonial or a claim of investment performance.